Table 1. Characteristics of studies included in the review and values of their effect measures with corresponding p-values.
| First author | Study year | Study country | Study design | Measured Poor outcome | Proportion of HIV infected participants | TB drug Susceptibility status of participants | Effect measured by | p-value reported | Sample size |
|---|---|---|---|---|---|---|---|---|---|
| Leiw, et al [37] | 2012 | Malaysia | Cross-sectional | Died, Failure, LTFU, and TO | 6.6% | Mixed participants | aOR | 0.011 | 21426 |
| Leung, et al [31] | 2001–2003 | Hong Kong | Cohort | Died, Failure, and LTFU | 0.43% | Susceptible | aOR | 0.001 | 15891 |
| Salami, et al [40] | 1991–1999 | Nigeria | Cross-sectional | Died, Failure, and LTFU | 4.25% | Not specified | COR | 0.001 | 1530 |
| Magee, et al [32] | 2009–2012 | Georgia | Cohort | Died, Failure, LTFU, and TO | 4.5% | MDR only | aRR | >0.05 | 1321 |
| Przybylski, et al [39] | 2001–2010 | Poland | Cross-sectional | Died, Failure, and LTFU | 0.4% | Not specified | COR | 0.930 | 1997 |
| Bonacci, et al [30] | 1995–2010 | Mexico | Cohort | Died, Failure, and LTFU | 2% | Mixed participants | aOR | 0.026 or 0.2* | 1022 |
| Yamana, et al [42] | 2010–2013 | Japan | Cross-sectional | Died | 0.1% | Not specified | aOR | 0.028 or 0.123** | 762 |
| Wang, et al [41] | 2002–2003 | Taiwan | Cross-sectional | Died, Failure, and LTFU | Not specified | Mixed participants | aHR | >0.05 | 523 |
| Gegia, et al [9] | 2011–2013 | Georgia | Cohort | Died, Failure, and LTFU | 1.35% | Mixed participants | aRR | <0.050 | 524 |
| Chiang, et al [43] | 2001–2003 | Taiwan | Case-control | Died, Failure, and LTFU | 0% | Susceptible | aOR | 0.047 or 0.073*** | 302 |
| Maruza, et al [33] | 2007–2009 | Brazil | Cohort | LTFU | 100% | Not specified | aOR | 0.007 | 273 |
| Masjedi, et al [28] | 2012–2014 | Iran | Clinical trial | Died, Failure, and LTFU | 0% | Susceptible | COR | 0.001 or 0.07**** | 334 |
| Roy, et al [44] | 2011 | India | Case-control | LTFU | Not specified | Not specified | aOR | 0.720 | 158 |
| Alo, et al [27] | 2010–2012 | Fiji Island | Cross-sectional | Died, Failure, and LTFU | Not specified | Not specified | COR | 0.500 | 375 |
| Ma, et al [38] | 2008–2011 | China | Cross-sectional | Died and Failure | Not specified | Not specified | chi2-test | 0.076 | 791 |
| Silva, et al [36] | 2005–2007 | Brazil | Cohort | Died | 70.8% | Not specified | COR | 0.570 | 140 |
| Pazarli, et al [34] | 2000–2005 | Turkey | Cohort | Died, Failure, and LTFU | 0% | MDR only | Chi2-test | 0.190 | 103 |
| Rathee, et al [35] | 2010–2011 | India | Cohort | Died, Failure, and LTFU | Not specified | Susceptible | Proportion | 0.000 | 101 |
| Awaisu, et al [29] | 2008–2009 | Malaysia | Quasi-experimental | LTFU and Failure | 0% | Susceptible | Chi2-test | 0.043 | 86 |
| Tabarsi, et al [26] | 2004–2007 | Iran | Cross-sectional | Died, Failure, and LTFU | 100% | Not specified | Proportion | >0.05 | 111 |
| Reed, et al [24] π | Not statedΨ | Republic of Korea | Cohort | Died | 0% | Mixed participants | aHR | 0.29 or 0.14***** | 657 |
| Tachfouti, et al [25] π | 2004–2009 | Morocco | Cohort | Failure | Not specified | Not specified | aOR | 0.030 | 727 |
aOR = adjusted odds ratio, COR = Crude odds ratio, aRR = adjusted risk ratio
aHR = adjusted hazard ratio, LTFU = Loss to follow-up, TO = transferred out
Ψpublished in 2013
πNot eligible for the meta-analysis
*p-value of 0.026 for heavy (≥11cigarette/day) & 0.2 for light smokers (<11 cigarette/day)
**p-value of 0.028 for >50packs/year smokers and 0.123 for ≤ 50packs/year smoker
***p-value of 0.047 for >20 cigarette/day smokers and 0.073 for 1-20/day
****p-value of 0.001 for smoker and 0.07 for quitters at treatment initiation
***** p-value of 0.29 for <1 pack/day smokers and 0.14 for ≥ 1 pack/day smokers